Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan:181:103896.
doi: 10.1016/j.critrevonc.2022.103896. Epub 2022 Dec 15.

Management of secondary immunodeficiency in hematological malignancies in the era of modern oncology

Nina Shah  1 , S Shahzad Mustafa  2 , Donald C Vinh  3
Affiliations
Free article
Review

Management of secondary immunodeficiency in hematological malignancies in the era of modern oncology

Nina Shah et al. Crit Rev Oncol Hematol. 2023 Jan.
Free article

Abstract

Secondary immunodeficiency (SID) in patients with B-cell hematological malignancies is a common condition that presents with recurrent infection. SID is due to both the inherent immune defects due to the malignancy, as well as secondary to cancer therapies, many of which have B-cell depleting properties. The early diagnosis of SID and the optimization of intervention strategies are key to delivering the most effective cancer treatments and reducing infection-related morbidity and mortality. This review discusses current practice, recommendations, and challenges for SID diagnosis, based on the evaluation of clinical history and laboratory assessments, and the effectiveness of specific vaccines and immunoglobulin replacement therapy in reducing the frequency and recurrence of infections in patients with SID, and the healthcare system-associated costs.

Keywords: Diagnosis; Hematological malignancy; Immunoglobulin; Immunoglobulin replacement therapy; Secondary immunodeficiency; Vaccination.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement NS has received research funding from Celgene/BMS, Janssen, Bluebird Bio, Sutro Biopharma, Teneobio, Poseida, and Nektar; and reports advisory role for GSK, Amgen, Indapta Therapeutics, Sanofi, CareDx, Kite, Karyopharm, and Oncopeptides. SSM reports speaker’s bureau for Genentech, GSK, Regeneron, AstraZeneca, and CSL Behring. DCV has received clinical trial support from CSL Behring, Cidara Therapeutics, and Janssen Pharmaceuticals; has received honoraria for advisory board consultations or speaker presentations from Merck Canada, CSL Behring, Novartis Canada, and UCB Biosciences GmbH; and has a patent application pending (Electronic Filing System ID: 40101099) and a report of invention submitted to McGill University (Track code: D2021–0043).

MeSH terms

Substances

LinkOut - more resources